4-PrO-DMT
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C15H20N2O2 |
Molar mass | 260.337 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
4-Propionoxy-N,N-dimethyltryptamine (4-PrO-DMT, or O-Propionylpsilocin) is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is theorized to act as a prodrug for psilocin. It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019.[1]
Recreational use
Dosage
4-PrO-DMT is reported to be orally active, though its threshold and duration are unstudied.
Effects
The effects of 4-PrO-DMT are broadly comparable to those of other serotonergic psychedelics such as LSD and psilocybin.
Some users have reported a minor audio distortion with lower dosages. Higher dosages increase the polarity of the distortion. It is defined as being slightly lower in pitch and creating several different effects, such as pitch bend, volume distortion, and rate distortion. As with most DiPT psychedelics, music can become more dissonant and less harmonious. Users have also reported a visual distortion widely comparable to the hallucinogen LSD.
Pharmacology
Pharmacodynamics
4-PrO-DMT is theorized to be a serotonergic psychedelic, and is partial agonist of the 5-HT1D, 5-HT1B and 5-HT1A serotonin receptors.
Similar to 4-Hydroxyl analogs of DMT, the 4-Propanoyloxy structure is what makes 4-PrO-DMT orally active, as DMT on its own requires a MAOI to be orally active.
Toxicity
Very little data about the toxicity or pharmacology of 4-PrO-DMT is known. Its chemical structure and pharmacological activity are similar to DMT, a compound which isn't associated with compulsive use or physical dependence. However, due to lack of research and data, it cannot be definitively concluded that its pharmacological actions in the human body do not differ from those of DMT. To date, there have been no reported deaths from 4-PrO-DMT.
See also
References
- ↑ European Monitoring Center for Drugs and Drug Addiction (December 2020). "New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System" (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262.
{{cite journal}}
: Cite journal requires|journal=
(help)
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
|